The favorable opinion from the European Patent Office is a critical step in securing intellectual property rights for Farudodstat, a key asset for ASLAN Pharmaceuticals. This exclusivity until at least 2043 not only protects the drug from competition but also significantly enhances its commercialization prospects in the European market. Given the importance of patents in the pharmaceutical industry, this development is likely to be viewed positively by investors, potentially leading to an increase in ASLN's stock price in the short term.